Christoph Sachsenmaier,,
and Jonathan A. Cooper*
Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109
Received 25 September 2001/ Returned for modification 6 November 2001/ Accepted 16 January 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
FAK, like the related molecule Pyk2/RAFTK (2, 61), is a nonreceptor protein tyrosine kinase that, aside from its catalytic domain, shares little homology with other protein tyrosine kinases. Most noticeably, it contains no SH2 or SH3 domain. It does, however, contain phosphotyrosines and proline-rich regions that bind SH2 or SH3 domains, respectively, of other molecules. Roles for FAK in many different integrin-stimulated cellular functions have been demonstrated, including attachment, spreading, proliferation, and survival (61). However, a major role for FAK downstream of integrins appears to be in the positive regulation of cell migration (49). FAK-/- cells exhibit reduced migration (29, 30), while cells overexpressing FAK display increased migration on FN (8, 48, 66).
Tyr397 in FAK, which is just amino terminal to the catalytic domain, is phosphorylated in response to FN stimulation and is critical for FAK function (61). Because phosphorylation at Y397 occurs both in bacteria (7) and in vitro (15, 58), it is believed to be autophosphorylated in vivo. Phosphorylated Y397 (pY397) serves as a binding site for the SH2 domain of Src or other SFKs (61). Substantial evidence suggests that pY397 is crucial for Src recruitment to FAK and for phosphorylation of the associated molecule Cas (9, 38, 47, 76). However, pY397 also can bind the SH2 domains of phosphatidylinositol 3'-kinase (PI3K) (10), phospholipase C-
(80), and Grb7 (26). It is not clear whether functional defects of Y397F FAK mutants result from lack of binding to Src, PI3K, phospholipase C-
, Grb7, or other unidentified proteins. However, a selective FAK mutation near Y397 that disrupts binding to PI3K but not Src is unable to promote cell migration (52). This result suggests that binding of PI3K is necessary for FAK-promoted cell migration and further suggests that pY397 may play multiple roles in FAK-regulated events downstream of integrins.
In many ways FAK acts as a scaffolding molecule. It is able to bind both the SH2 and SH3 domains of Src (61, 70). FAK also binds several other signaling and cytoskeletal molecules (61). For example, FAK pY925 binds Grb2, an interaction that is believed to be important for cell proliferation in response to integrin activation. Through carboxy-terminal proline-rich regions, FAK binds Cas, a scaffolding molecule whose tyrosine phosphorylation is important for regulating cell migration (47). In addition, FAK binds paxillin, whose phosphorylation is also believed to be important in cell spreading and migration events (74). FAK binding to talin (11) has been proposed to mediate an indirect interaction between FAK and the ß subunit of integrin receptors, although a direct interaction with integrin ß1 has also been demonstrated (59). Therefore, an important function of FAK appears to be as a scaffold to recruit cytoskeletal and signaling molecules involved in integrin-dependent events.
SFKs have been shown to play important roles in signaling downstream of integrin receptors, and the role of Src in particular has been best characterized. Src associates directly with several focal adhesion proteins, including FAK, Cas, and paxillin (5). Although the catalytic activity of Src increases only modestly after integrin stimulation (33, 42, 67), Src (or another SFK) appears to directly phosphorylate many signaling and cytoskeletal proteins involved in integrin-mediated events, including FAK, Cas, paxillin, cortactin, and tensin (38, 72, 75, 76). In fibroblasts, SFKs are believed to regulate integrin-mediated attachment and spreading (17, 32, 33), focal adhesion remodeling and turnover (21, 75), integrin-cytoskeletal tension (17), and cell migration (21, 38). Src has been shown to mediate these events in both kinase-dependent and -independent manners, and it is unclear whether its main function in integrin signaling is that of a kinase or a scaffolding molecule. Support for the former comes from the demonstration that most proteins tyrosine phosphorylated following integrin activation are direct substrates of Src (5). In contrast, a kinase-defective (KD) Src molecule (KD-Src) expressed in src-/- cells rescued cell spreading on FN to a similar level to that rescued by wild-type (wt) Src (wtSrc) (33) and was able to partially rescue osteoclast defects in src-/- mice (63). Furthermore, truncated Src molecules containing only the SH2 and SH3 domains (and not the kinase domain) were able to rescue integrin signaling events such as FAK and Cas phosphorylation and src-/- cell spreading (33, 60).
Existing models for FAK and Src functions in integrin signaling have placed FAK upstream of Src (61). It has been proposed that FAK autophosphorylates at Y397 and recruits Src through its SH2 domain and that this Src-FAK interaction is stabilized by Src's SH3 domain (70). Once this complex is formed, the inhibitory Src SH2-pY527 intramolecular interaction is disrupted, increasing Src catalytic activity. Src then phosphorylates additional sites on FAK, including the regulatory loop tyrosines in FAK's kinase domain (Y576 and Y577) to further promote FAK catalytic activity and thus autophosphorylation at Y397 (7). Other sites phosphorylated by Src include FAK Y925, which then recruits Grb2, and sites on associated molecules such as Cas and paxillin.
It has been shown that in SYF mutant fibroblasts there is very little induction of tyrosine phosphorylation of any protein, including FAK, following integrin stimulation (38). This suggests that Src is upstream of FAK and raises questions about how Src is activated and how it then regulates the phosphorylation of FAK. In this study we expressed wt or c-Src point mutants at near-normal levels in SYF fibroblasts, thus creating a system whereby the introduced Src is the only SFK available in these cells. We found that Src kinase activity is required for most functions in integrin signaling. A KD-Src molecule only elicited a delayed rescue of FAK phosphorylation at Y397, suggesting that Src scaffolding functions play a secondary role in these events. In addition, point mutations in either the SH2 or SH3 domain of Src did not diminish the rescue of protein phosphorylation or cell migration. These results indicate that the primary function of Src in integrin signaling is as a kinase.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Antibodies. Anti-Src monoclonal antibody (MAb) LA074 was produced from LP-016 mouse hybridoma cells (NCI Repository, Viromed Biosafety Laboratories, Camden, N.J.) and diluted from an unpurified cell supernatant. This monoclonal antibody was raised against amino acids 2 to 17 of v-Src and is also known as SCRF 35.4 or Src MAb 2-17. The rabbit polyclonal anti-KC FAK serum was a kind gift of Jun-Lin Guan (Cornell University). The SRC2, anti-FAK C20, and anti-Cas C20 rabbit polyclonal antibodies were purchased from Santa Cruz Biotechnology, Inc. Anti-paxillin was purchased from Zymed Laboratories, Inc., and the mouse MAb anti-FAK used for immunofluorescence staining of cells was purchased from BD Transduction Laboratories. The anti-phosphotyrosine MAb 4G10 was purchased from Upstate Biotechnology, Inc. The site-specific rabbit polyclonal phosphoantibodies anti-Src pY418 (here called anti-Src pY416 to denote chicken c-Src numbering), anti-FAK pY397, and anti-FAK pY576 were purchased from Biosource International, Inc.
Generation of Src point mutations. pLXSH retroviral vectors containing wt chicken c-Src, the KD K295R mutant, or the activated Y527F mutant were described previously (4, 38). pGEX vectors encoding glutathione transferase (GST) fusion proteins with the SrcSH2 (14) or SrcSH3 (4) domain were also described previously. Point mutations in Src (D386A, T215W, D99N, and Y416F) were generated by the QuikChange (Stratagene) technique, as described previously (28). The restriction sites AflII, NdeI, SacI, and EcoRI were introduced to mark the mutations at amino acid positions 99, 215, 386, and 416, respectively, and did not result in coding changes. Sequence analysis indicated that no additional mutations were introduced.
Cell migration assays. Cells were harvested with 0.25% trypsin and 2 mM EDTA in phosphate-buffered saline (PBS), washed once with 0.5 mg of soybean trypsin inhibitor/ml in DMEM, washed twice with DMEM, and resuspended in DMEM at 250,000 cells/ml. The lower wells of a 48-well chemotaxis chamber (NeuroProbe, Inc.) were loaded with 0 or 10 µg of bovine FN/ml in DMEM. An 8-µm-pore-diameter porous membrane (NeuroProbe, Inc.) separated the lower and upper chambers, and cells were added to the upper wells. The chamber was incubated at 37°C for 3 h, and the cells were fixed and stained by using a HEMA3 stain set. The cells on the upper side of the membrane were removed, and the migrated cells on the lower side were counted by using a light microscope at x400 magnification. Each experiment was repeated at least three times with 11 wells for each cell type.
Cell spreading assays. Cells were harvested with 0.25% trypsin and 2 mM EDTA in PBS, washed once with 0.5 mg of soybean trypsin inhibitor/ml in DMEM, washed twice with DMEM, and resuspended in HEPES-buffered DMEM/F-12 medium (Invitrogen Life Technologies-Gibco) at 200,000 cells/ml. Cells were allowed to recover at 37°C for 30 to 60 min and were then plated on dishes coated with 5 µg of bovine FN/ml. Time-lapse phase contrast images were taken at the indicated times by using a Nikon TE300 microscope with a stage heated to 37°C, a cooled charge-coupled device camera, and Metamorph Software. Cells were scored as spread or not; the percent spread for each cell line from a representative experiment is shown in Fig. 1C. The experiment was repeated at least three times with similar results.
|
Immunoprecipitations were performed by first incubating the indicated primary antibodies with the cell lysates for 3 h or overnight at 4°C. When mouse or rabbit antibodies were used to immunoprecipitate, protein A-immobilized Sepharose CL-4B beads (Sigma) were added with or without rabbit anti-mouse immunoglobulin G, respectively, and incubated for 1 h at 4°C. Immunoprecipitates were washed four times with the appropriate lysis buffer and resuspended in either electrophoresis sample buffer for Western blotting or kinase buffer.
SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting were performed essentially as previously described (46), with two exceptions. First, to separate Src from the immunoglobulin G heavy chain in immunoprecipitates, an SDS-7% PAGE gel with a 20:1 acrylamide/bisacrylamide ratio was used. Second, for Western blotting with the FAK anti-KC serum, 5% milk protein was used as a blocking agent in place of the usual bovine serum albumin block. Following incubation with the indicated primary antibody, one of the following horseradish peroxidase-conjugated secondary reagents was used: goat anti-mouse, goat anti-rabbit, or protein A (Bio-Rad). Immunoreactive proteins were visualized with the Renaissance chemiluminescence reagent (NEN).
Immunofluorescence staining of cells. Glass coverslips were coated with 5 µg of bovine FN/ml in PBS for 2 h at RT and washed with PBS. Cells were harvested with 0.25% trypsin and 2 mM EDTA in PBS, washed once with 0.5 mg of soybean trypsin inhibitor/ml in DMEM, washed twice with DMEM, and resuspended in DMEM containing 0.5% fetal bovine serum (FBS). Cells were plated on coated coverslips for 1 h at 37°C and washed briefly with PBS. For FAK staining, cells were fixed and permeabilized simultaneously with 4% paraformaldehyde and 0.5% Triton X-100 in PBS for 10 min. For Src and paxillin staining, cells were first fixed with 4% paraformaldehyde in PBS for 10 min, washed, and then permeabilized with 0.5% Triton X-100 in PBS for 10 min. Coverslips were incubated with blocking solution (1% [wt/vol] bovine serum albumin in PBS) for 1 h at RT. First primary and then secondary antibodies (fluorescein isothiocyanate [FITC]- or Texas Red-conjugated donkey anti-mouse or anti-rabbit; Jackson Immunoresearch) were diluted in blocking solution and incubated at RT for 1 h, with washes using PBS in between the two incubations. Cells were then washed with PBS and distilled H20 and mounted with Prolong Antifade (Molecular Probes). Fluorescence photomicrographs were taken at x400 magnification on a Nikon TE300 microscope using a cooled charge-coupled device camera and Metamorph Software.
GST fusion protein expression, purification, and binding assays. GST-fusion proteins were expressed and purified as described previously (46) and quantitated by SDS-PAGE and Coomassie staining. Actively growing NIH3T3 cells were either washed with cold PBS and lysed in Triton or RIPA lysis buffer or harvested with 0.25% trypsin and 2 mM EDTA in PBS, washed once with DMEM containing 10% FBS, washed twice with DMEM, washed once with cold PBS, and lysed in suspension. Interaction assays were performed by incubating 10 to 30 µg of GST fusion protein (coupled to glutathione beads) with 150 to 350 µg of NIH3T3 lysate, incubating for 3 h at 4°C, and washing three times with lysis buffer. Bound proteins were resolved with SDS-PAGE and detected by Western blotting as indicated.
In vitro kinase assays.
FAK immunoprecipitates using anti-FAK C20 were washed on ice three times with lysis buffer and twice with 20 mM Tris (pH 7.4) and resuspended in kinase buffer (20 mM Tris [pH 7.4], 10 mM MnCl2, 1 µM ATP). Immunoprecipitates were incubated in kinase buffer containing 10 µCi of [
-32P]ATP and 10 µg of poly(Glu, Tyr) (4:1) (Sigma) as a substrate for 20 min at RT, and then the reaction was stopped by the addition of electrophoresis sample buffer. Samples were boiled, resolved by SDS-PAGE, and visualized by autoradiography. Densitometric analysis was used to normalize FAK protein levels and determine relative poly(Glu, Tyr) phosphorylation in each sample.
Src immunoprecipitates using MAb LA074 were washed on ice three times with RIPA lysis buffer, once with buffer A (10 mM PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid] [pH 7.0], 100 mM NaCl, 20 µg of aprotinin/ml) containing 0.5% NP-40, and once with buffer A. Rabbit muscle enolase (Sigma) was denatured with 50 mM acetic acid for 5 min at 30°C and buffered with 1 M PIPES (pH 7.0). Immunoprecipitates were incubated in buffer B (20 mM PIPES [pH 7.0], 10 mM MnCl2, 20 µg of aprotinin/ml, 1 µM ATP) with 1 µCi of [
-32P]ATP and 1.5 µg of acid-denatured enolase as a substrate for 10 min at RT, and the reaction was stopped by the addition of electrophoresis sample buffer. Samples were boiled, resolved by SDS-PAGE, and visualized by autoradiography.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
|
|
Regulation of integrin-induced events by Src does not require a functional SH2 or SH3 domain. We determined the level of integrin-induced FAK phosphotyrosine in cells expressing Src SH2 and SH3 domain mutants. The T215W or the D99N or a double D99N/T215W mutant supported integrin-induced FAK phosphorylation detected by 4G10 (Fig. 7A). When we examined FAK phosphorylation specifically at Y397 or Y576, we also found that the SH2 and SH3 mutants supported FAK phosphorylation (Fig. 7C and D), although some sites may not have been phosphorylated as well as when wtSrc was expressed. In addition, FAK phosphorylation in these cells did not occur in the absence of integrin activation when cells were in suspension, unlike in cells expressing an activated Y527F Src mutant (Fig. 7). These data provide further evidence that the T215W and D99N Src mutants are not catalytically deregulated. Thus, the ability of Src to stably associate with FAK is neither necessary nor sufficient for its rescue of FAK phosphorylation at Y397 and Y576.
Because the ability of Src SH2 and SH3 mutants to rescue FAK phosphorylation might be an isolated event, we asked whether other Src-dependent functions downstream of integrins required scaffolding functions provided by these domains. The profiles of phosphorylated proteins induced by integrin activation were similar in cells expressing wtSrc or the T215W, D99N, or T215W/D99N Src mutants (Fig. 1A and not shown). Moreover, the T215W and D99N Src mutants supported FN-stimulated phosphorylation of Cas and paxillin (Fig. 7E to H). We also examined biological responses of cells to integrin stimulation and found that migration (Fig. 1B) and spreading (Fig. 1C and D) were fully rescued in cells expressing the T215W, D99N, or T215W/D99N mutants. Therefore, scaffolding functions through the SH2 or SH3 domains of Src are dispensable for many of its functions in integrin signaling.
Overexpression of KD-Src can allow some scaffolding functions to occur. Because there have been reports of integrin signaling by KD-Src (33, 60), we examined cells expressing high levels of either wtSrc or KD-Src (Fig. 8A). These cells express much higher levels of Src than the cells used in the preceding experiments. We found that cells expressing high levels of wtSrc promoted FAK phosphorylation independently of FN stimulation (Fig. 8B). High levels of KD-Src permitted a significant level of FN-induced FAK phosphorylation (Fig. 8B), including at Y397 (data not shown). While FAK phosphorylation promoted by high KD-Src expression was below that promoted by a similarly high level of wtSrc, it was at least as high as that promoted by a low level of wtSrc (Fig. 8B). Likewise, at low levels of expression, Src kinase activity was required for FN-induced Cas phosphorylation, but at higher levels KD-Src could promote Cas phosphorylation (Fig. 8D). Preliminary results indicate that high levels of KD-Src can also promote an intermediate level of paxillin phosphorylation (not shown). These data suggest that Src is able to function as a scaffold in the absence of catalytic activity when overexpressed. However, at normal levels KD-Src does not support phosphorylation of FAK or Cas at any sites other than the FAK autophosphorylation site (Y397) (Fig. 2).
Because KD-Src can rescue FAK pY397 (Fig. 2D), which is believed to be a site of autophosphorylation, we asked if KD-Src might function by either promoting FAK catalytic activity or protecting this site from dephosphorylation. FAK immunoprecipitates from SYF cells expressing low or high levels of wtSrc or KD-Src were used for in vitro kinase assays, using [
-32P]ATP and poly(Glu, Tyr) as a substrate (Fig. 8F). In SYF cells, only basal FAK activity was detected and was not increased upon integrin stimulation. In cells expressing wtSrc (either low or high levels), FAK catalytic activity was increased upon integrin activation. Interestingly, high levels of KD-Src expression also promoted an intermediate increase in FAK activity, while low KD-Src levels did not. These data suggest that high KD-Src expression promotes FAK activity and Y397 autophosphorylation, and may promote FAK-mediated phosphorylation of other proteins, including Cas and paxillin. We also asked if KD-Src might protect FAK pY397 from dephosphorylation. In SYF cells expressing wtSrc, treatment with the tyrosine phosphatase inhibitor sodium vanadate promoted phosphorylation of many proteins (Fig. 8H). FAK was included among these proteins, as vanadate-increased FAK phosphorylation was especially apparent in suspended cells where FAK is normally dephosphorylated (Fig. 8G). However, vanadate treatment did not promote FAK phosphorylation in SYF cells (Fig. 8G). These results suggest that while vanadate treatment did inhibit many phosphatases, including those that dephosphorylate FAK, this alone was not sufficient to allow FAK phosphorylation in the absence of SFKs.
| DISCUSSION |
|---|
|
|
|---|
Nontransforming Src SH2 and SH3 domain mutants. Src mediates interactions with several focal adhesion proteins through its SH2 and SH3 domains (5). To address the roles of these interactions, we generated mutations to reduce SH2 and SH3 domain binding. Because deregulation of Src catalytic activity can result from disruption of either SH2- or SH3-mediated intramolecular interactions (5, 16, 64), we sought to disrupt only intermolecular interactions of Src. The SH2 domain mutation T215W alters the binding specificity from pYEEI to pYENP, and reduces binding to FAK pY397AEI (43). Structural studies of Src (36, 77, 79) demonstrate that the T215W mutation reduces the size of the +3 hydrophobic binding pocket to physically prevent an Ile from binding. However, because residues flanking Src pY527QPG are not docked into the SH2 domain (79), the T215W mutation was not predicted to affect Src intramolecular binding. Similarly, structural evidence based on the Src SH3 domain (18, 79) has shown that Asp99 creates a salt bridge with an important Arg near the consensus PXXP sequence of the ligand (RXLPPLP for a class I ligand and PPLPXR for a class II ligand, where X is any amino acid) (5, 54). It was shown that a D99K mutation reduces SH3-mediated binding (16), while a D99N mutation only reduces binding to Arg-containing ligands (78). Because the SH2-kinase linker contains a Leu instead of an Arg at this position (i.e., the L in P250QTQGL) (65), we predicted that the D99N mutation would only disrupt intermolecular interactions and thus would not deregulate Src catalytic activity. Various assays showed that neither the T215W, D99N, nor double D99N/T215W mutant was overly active when expressed in SYF cells, unlike the Y527F activated mutant (Fig. 5). However, binding of the Src SH2 or SH3 domain to various partners, including FAK, Cas, and paxillin (Fig. 6), was greatly reduced by the T215W or D99N mutation, respectively. Likewise, association of Src with FAK in cells was nearly abolished by either of these mutations (Fig. 6). The T215W and D99N mutants thus provide useful tools for studying the significance of intermolecular SH2 and SH3 interactions without deregulating Src catalytic activity.
Regulation of Src by integrins. Some previous studies have demonstrated an increase in Src catalytic activity upon integrin stimulation; however, this increase is generally very weak (two- to threefold) (33, 42, 67). Despite repeated attempts, we did not detect increased Src catalytic activity (not shown) or Y416 phosphorylation (Fig. 3) upon integrin activation. By indirect immunofluorescence, a very small fraction of wtSrc-expressing cells (1% or less) demonstrated increased anti-pY416 signal (Fig. 4). It is possible that integrin induction of Src activity may be cell type specific, dependent, for example, on expression levels of Src or of tyrosine phosphatases. However, we propose that, while Src basal kinase activity is clearly required for integrin signaling, the ability to regulate this activity through Y416-dependent mechanisms is not.
Consistent with this, we found that a Y416F Src mutant was fully able to rescue FAK phosphorylation (Fig. 3), cell spreading, and cell migration (Fig. 1). Structural studies of SFKs predict that Y416 phosphorylation is important for regulating Src kinase activity (reviewed in reference 65), and pY416 levels correlate with in vitro Src activity (3). The Y416F mutation in c-Src, v-Src, or various activated forms of c-Src has been shown to decrease its in vitro activity and transforming abilities (19, 39, 40, 51, 68). While Src-dependent phosphorylation of some unidentified proteins in SYF cells might be reduced by the Y416F mutation (Fig. 1), overall this mutation had little effect (Fig. 1 and 3). It is possible that Y416-dependent effects are seen when Src is expressed at higher levels or in combination with endogenous Src or other SFKs. It is also possible that Src-dependent transformation requires Y416, while integrin-mediated responses do not. Further evidence that Src catalytic regulation is not important for integrin signaling comes from the activated Y527F Src mutant expressed in SYF cells. While protein phosphorylation (including FAK) was high in suspended cells expressing this mutant, it was further promoted by integrin stimulation (Fig. 1 and 7). Because the Y527F mutant already has extremely high catalytic activity, this result suggests that integrin stimulation promotes phosphorylation other than by changing Src activity. Taken together, these results indicate that while basal Src kinase activity is clearly required for its regulation of integrin-mediated events, Y416-dependent regulation of this activity is not important and may not occur.
Furthermore, we found that wtSrc was not concentrated in focal adhesions, but rather seemed to be localized to the plasma membrane and endosomes (Fig. 4). The presence of c-Src in focal adhesions has long been presumed, based on its known functional roles, but demonstrations of this have been lacking. In contrast, the truncated Src251 molecule is clearly found in focal adhesions (17, 32, 73), as are activated v-Src, activated Y527F mutant, and c-Src expressed in the absence of Csk (20, 21, 27, 73). Simultaneous overexpression of both c-Src and FAK also promotes Src localization to focal adhesions, while overexpression of c-Src alone does not (57). In contrast, when localization of nonactivated full-length c-Src has been examined, it was found to be primarily perinuclear and in endosomes, with perhaps only a weak detection in focal adhesions (32-34, 53, 57, 64, 73). Detection of activated Src using the clone 28 MAb has shown that it appears concentrated in perinuclear, plasma membrane, and cytoskeletal regions of the cell (35, 41). Using anti-pY416, we saw a similar pattern of active wtSrc localization in SYF cells (Fig. 4). In light of these data, we conclude that while Src can be forced to go to focal adhesions under some conditions, normally it is not concentrated there upon integrin activation. Therefore, Src must exert its effects on downstream mediators through a mechanism independent of strong association.
FAK phosphorylation upon integrin activation: role of Src. We have made several observations about the regulation of FAK phosphorylation by Src, only some of which are consistent with a standard model of their interactions (61). First, we found that FAK can autophosphorylate at Y397 independently of Src, but Src also regulates FAK Y397 phosphorylation, perhaps directly (Fig. 2), which is consistent with the findings of a recent study (56). In addition, KD-Src can promote FAK autophosphorylation at Y397, particularly at later times (Fig. 2). Second, Src kinase activity was required for rapid and full phosphorylation of FAK at other sites (Fig. 2). It has been proposed that Src promotes FAK catalytic activity (and Y397 autophosphorylation) by upregulating pY576 and/or pY577. Consistent with this, FAK pY576 was not detected in cells expressing KD-Src at low levels (Fig. 2). Third, in contrast to the standard model, Src-mediated phosphorylation of FAK did not require stable association. Both the T215W and D99N mutants (or the double D99N/T215W mutant) promoted FAK phosphorylation at multiple sites (pY397, pY576, and 4G10-detected sites) as well as wtSrc (Fig. 7).
One possible explanation for these seemingly conflicting results stems from the prior use of a Y397F FAK mutant, which has been assumed to specifically reduce stable association with Src. While reduced FAK-Src association is clearly one result of this mutation, we found that a Src T215W mutant does not function analogously to a FAK Y397F mutant. For example, phosphorylation of the FAK activation loop (Y576/Y577) by Src is severely reduced by the FAK Y397F mutation (48, 55, 57, 66) but is not affected by the Src T215W mutation (Fig. 7). It is possible that elimination of the phosphotyrosine affects binding far more severely than mutation of the SH2 domain binding pocket. While it is clear that T215W Src has reduced affinity for FAK (Fig. 6), we cannot rule out the possibility that some remaining weak association is sufficient for subsequent events to occur at wt levels. Consistent with our results, it has been shown that v-Src can phosphorylate a Y397F FAK mutant in the absence of their stable association (44). It is possible, therefore, that Src association with pY397 of FAK may be entirely dispensable and pY397 instead may be required for some other function, such as binding molecules other than Src (10, 26, 80) or inducing a conformational change to affect FAK function.
Interestingly, when expressed at normal levels, KD-Src was able to rescue FAK phosphorylation at Y397 but not at other sites (Fig. 2). This result suggests that through some scaffolding function, Src might either promote phosphorylation or protect from dephosphorylation at this site. We observed that high levels of KD-Src promoted FAK catalytic activity (Fig. 8F), and while this was not observed with low levels of KD-Src, it could account for some FAK pY397 seen in these cells. The lack of FAK phosphorylation in SYF cells treated with sodium vanadate (Fig. 8G) argues against simple inhibition of a phosphatase as a mechanism, although we did not look specifically at pY397. Likewise, full rescue of FAK pY397 by the Src T215W mutant, which has greatly reduced affinity for FAK, also argues against simple SH2-mediated protection from phosphatases. Because the Src T215W mutant also promotes FAK pY576 (Fig. 7) and presumably Y397 autophosphorylation, the analysis of an SH2 domain protective role becomes complicated. It is also possible that KD-Src regulates a phosphatase through a more indirect mechanism, or that a vanadate-insensitive phosphatase is at work.
Does Src function as a kinase or a scaffold to regulate integrin signaling? Src is believed to play important catalytic roles in the regulation of integrin signaling events. For example, phosphorylation of Cas to promote cell migration (9, 12, 13, 37, 47) is significantly reduced in cells lacking SFKs but is not affected by the absence of FAK (38, 76). More specifically, although FAK is believed to phosphorylate a tyrosine on Cas, this site is thought to recruit Src (69) to allow Src-mediated Cas phosphorylation at multiple YXXP motifs, which mediate binding to Crk to promote cell migration (6, 50, 69). Thus, Src (or another SFK) and not FAK is believed to be the kinase primarily responsible for Cas phosphorylation subsequent to integrin activation. Likewise, integrin-induced phosphorylation of other proteins, such as paxillin, tensin, and cortactin, is reduced or eliminated by the absence of SFKs but is not affected in FAK-/- cells (29, 38, 72, 75). On the other hand, kinase-independent functions for Src in integrin signaling have also been demonstrated. Expression of KD-Src or truncated molecules (Src251 or Src1-298) in src-/- cells rescued cell spreading and phosphorylation events (33, 60). Thus, it has been proposed that scaffolding functions of Src, mediated through both its SH2 and SH3 domains, may play important roles in integrin-mediated signaling events.
In the cells used here, we have found that the scaffolding functions of Src are dispensable for its regulation of integrin signaling events, while its catalytic activity is crucial, because KD-Src was impaired while SH2 and SH3 mutants were fully functional (Fig. 1). However, low levels of KD-Src were able to rescue a delayed phosphorylation of FAK Y397 (Fig. 2), and high levels further promoted FAK and Cas phosphorylation (Fig. 8). It is likely that high levels of KD-Src may overpower Csk phosphorylation of Y527, resulting in an unfolded KD-Src molecule with exposed SH2 and SH3 domains. It is possible that high KD-Src expression accounted for its rescue of src-/- cell spreading (33). Clearly, Src molecules containing exposed SH2 and SH3 domains such as Src251 and Src1-298 are functional in some systems (33, 60). However, these data may not represent true functions of Src; in fact, Src1-298 promoted FAK phosphorylation in suspended cells (60), suggesting that it binds proteins in a deregulated manner. Taken together, these data suggest that Src scaffolding functions can occur under certain conditions, such as by overexpression of a Src molecule. However, our data demonstrate that under normal circumstances, Src scaffolding functions are not needed (or that a very weak level of binding is sufficient) for events that we have examined. The lack of enrichment of Src in focal adhesions (Fig. 4) supports this idea, as it suggests that while Src substrates and effectors are primarily localized there, Src itself is at best only transiently present.
To reconcile these new observations, we propose several possible new models to describe Src function in integrin signaling (Fig. 9B and C). First, it is possible that the previous models are accurate (Fig. 9A), with the exception that only very weak association of Src with its substrates (both subcellularly and molecularly) is sufficient for its functions. A variation on this hypothesis is that pY397 of FAK might be required, not for binding to Src, but for indirect regulation of Src phosphorylation events through some other protein (X) (Fig. 9B). Basally active Src is present throughout the plasma membrane, and presumably is continually phosphorylating its substrates. X could be a widely distributed phosphatase that dephosphorylates Src substrates. If X were locally inhibited by FAK, phosphorylated substrates would locally accumulate. Note that phosphate turnover on focal adhesion proteins is believed to be very rapid when cells are placed in suspension. Candidates for this phosphatase might include SHP-2, PTP1B, or PTP-PEST, which are believed to regulate integrin-induced phosphorylation events (1). A third possibility is that Src may phosphorylate another protein (Y) (Fig. 9C), which allows FAK to phosphorylate proteins like Cas and paxillin, or that Y is itself the kinase that carries out these reactions. This model is attractive in that it requires Src to act only on Y but not on FAK or Cas. Y could also be a phosphatase that is inhibited by Src to allow FAK-mediated phosphorylation events to occur. The fact that high levels of KD-Src expression allow some phosphorylation events to occur suggests that FAK (or another kinase) can carry out these reactions. The lack of substrate phosphorylation in SFK-null cells may therefore be a result of insufficient activation of a downstream kinase or insufficient inhibition of a downstream phosphatase.
|
| ACKNOWLEDGMENTS |
|---|
L.A.C. is supported by postdoctoral National Research Service Award CA88447-02 from the National Institutes of Health (NIH). This work was supported by grants CA54786 and CA41072 from the NIH.
| FOOTNOTES |
|---|
Present address: CEPTYR, Inc., Bothell, WA 98021. ![]()
Present address: ProQinase GmbH, D-79106 Freiburg, Germany. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Avraham, H., S. Y. Park, K. Schinkmann, and S. Avraham. 2000. RAFTK/Pyk2-mediated cellular signalling. Cell. Signal. 12:123-133.[CrossRef][Medline]
3. Boerner, R. J., D. B. Kassel, S. C. Barker, B. Ellis, P. DeLacy, and W. B. Knight. 1996. Correlation of the phosphorylation states of pp60c-src with tyrosine kinase activity: the intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated. Biochemistry 35:9519-9525.[CrossRef][Medline]
4.
Brown, M. T., J. Andrade, H. Radhakrishna, J. G. Donaldson, J. A. Cooper, and P. A. Randazzo. 1998. ASAP1, a phospholipid-dependent Arf GTPase-activating protein that associates with and is phosphorylated by Src. Mol. Cell. Biol. 18:7038-7051.
5. Brown, M. T., and J. A. Cooper. 1996. Regulation, substrates and functions of src. Biochim. Biophys. Acta 1287:121-149.[Medline]
6.
Burnham, M. R., P. J. Bruce-Staskal, M. T. Harte, C. L. Weidow, A. Ma, S. A. Weed, and A. H. Bouton. 2000. Regulation of c-SRC activity and function by the adapter protein CAS. Mol. Cell. Biol. 20:5865-5878.
7. Calalb, M. B., T. R. Polte, and S. K. Hanks. 1995. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol. Cell. Biol. 15:954-963.[Abstract]
8. Cary, L. A., J. F. Chang, and J. L. Guan. 1996. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J. Cell Sci. 109:1787-1794.[Abstract]
9.
Cary, L. A., D. C. Han, T. R. Polte, S. K. Hanks, and J. L. Guan. 1998. Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration. J. Cell Biol. 140:211-221.
10.
Chen, H. C., P. A. Appeddu, H. Isoda, and J. L. Guan. 1996. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J. Biol. Chem. 271:26329-26334.
11.
Chen, H. C., P. A. Appeddu, J. T. Parsons, J. D. Hildebrand, M. D. Schaller, and J. L. Guan. 1995. Interaction of focal adhesion kinase with cytoskeletal protein talin. J. Biol. Chem. 270:16995-16999.
12.
Cheresh, D. A., J. Leng, and R. L. Klemke. 1999. Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J. Cell Biol. 146:1107-1116.
13.
Cho, S. Y., and R. L. Klemke. 2000. Extracellular-regulated kinase activation and CAS/Crk coupling regulate cell migration and suppress apoptosis during invasion of the extracellular matrix. J. Cell Biol. 149:223-236.
14.
Duyster, J., R. Baskaran, and J. Y. Wang. 1995. Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc. Natl. Acad. Sci. USA 92:1555-1559.
15. Eide, B. L., C. W. Turck, and J. A. Escobedo. 1995. Identification of Tyr-397 as the primary site of tyrosine phosphorylation and pp60src association in the focal adhesion kinase, pp125FAK. Mol. Cell. Biol. 15:2819-2827.[Abstract]
16. Erpel, T., G. Superti-Furga, and S. A. Courtneidge. 1995. Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra- and intermolecular interactions. EMBO J. 14:963-975.[Medline]
17. Felsenfeld, D. P., P. L. Schwartzberg, A. Venegas, R. Tse, and M. P. Sheetz. 1999. Selective regulation of integrincytoskeleton interactions by the tyrosine kinase Src. Nat. Cell Biol. 1:200-206.[CrossRef][Medline]
18.
Feng, S., J. K. Chen, H. Yu, J. A. Simon, and S. L. Schreiber. 1994. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science 266:1241-1247.
19. Ferracini, R., and J. Brugge. 1990. Analysis of mutant forms of the c-src gene product containing a phenylalanine substitution for tyrosine 416. Oncogene Res. 5:205-219.[Medline]
20.
Fincham, V. J., V. G. Brunton, and M. C. Frame. 2000. The SH3 domain directs acto-myosin-dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase. Mol. Cell. Biol. 20:6518-6536.
21. Fincham, V. J., and M. C. Frame. 1998. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility. EMBO J. 17:81-92.[CrossRef][Medline]
22. Furuta, Y., D. Ilic, S. Kanazawa, N. Takeda, T. Yamamoto, and S. Aizawa. 1995. Mesodermal defect in late phase of gastrulation by a targeted mutation of focal adhesion kinase, FAK. Oncogene 11:1989-1995.[Medline]
23. George, E. L., E. N. Georges-Labouesse, R. S. Patel-King, H. Rayburn, and R. O. Hynes. 1993. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119:1079-1091.[Abstract]
24. Giancotti, F. G., and E. Ruoslahti. 1999. Integrin signaling. Science 285:1028-1032.
25.
Gibbs, C. S., and M. J. Zoller. 1991. Rational scanning mutagenesis of a protein kinase identifies functional regions involved in catalysis and substrate interactions. J. Biol. Chem. 266:8923-8931.
26.
Han, D. C., and J. L. Guan. 1999. Association of focal adhesion kinase with Grb7 and its role in cell migration. J. Biol. Chem. 274:24425-24430.
27.
Howell, B. W., and J. A. Cooper. 1994. Csk suppression of Src involves movement of Csk to sites of Src activity. Mol. Cell. Biol. 14:5402-5411.
28. Howell, B. W., T. M. Herrick, J. D. Hildebrand, Y. Zhang, and J. A. Cooper. 2000. Dab1 tyrosine phosphorylation sites relay positional signals during mouse brain development. Curr. Biol. 10:877-885.[CrossRef][Medline]
29. Ilic, D., Y. Furuta, S. Kanazawa, N. Takeda, K. Sobue, N. Nakatsuji, S. Nomura, J. Fujimoto, M. Okada, and T. Yamamoto. 1995. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377:539-544.[CrossRef][Medline]
30. Ilic, D., S. Kanazawa, Y. Furuta, T. Yamamoto, and S. Aizawa. 1996. Impairment of mobility in endodermal cells by FAK deficiency. Exp. Cell Res. 222:298-303.[CrossRef][Medline]
31. Johnson, L. N., M. E. Noble, and D. J. Owen. 1996. Active and inactive protein kinases: structural basis for regulation. Cell 85:149-158.[CrossRef][Medline]